Vyleesi and Sildenafil Interaction: What Women Need to Know Before Combining These Drugs

Why This Interaction Matters, and Who Is Actually at Risk

The short answer: you should not take bremelanotide and sildenafil at the same time. The FDA prescribing information for bremelanotide explicitly lists sildenafil as a drug interaction requiring avoidance because the combination can produce additive hypotension.

The clinical picture is more nuanced than a flat prohibition, and understanding it helps you have a smarter conversation with your prescriber.

Who uses sildenafil and might also need Vyleesi?

Sildenafil is not a drug used only by men. Women take sildenafil for two documented reasons:

1. Pulmonary arterial hypertension (PAH) under the brand name Revatio, at doses of 20 mg three times daily. PAH affects women at a 4:1 ratio compared with men, making this a genuinely female-dominant indication.
2. Off-label sexual dysfunction, including low arousal and difficulty achieving orgasm, at doses typically ranging from 25 to 100 mg as needed. Evidence for this use in women is modest and mixed, but some clinicians do prescribe it.

If you fall into either group and you have also been diagnosed with hypoactive sexual desire disorder (HSDD), you may wonder whether adding bremelanotide makes sense. The interaction data says the answer is no, at least not concurrently.

How common is HSDD in the population who might be on sildenafil?

HSDD affects approximately 8 to 10 percent of premenopausal women when defined by distress criteria. Among women with PAH, quality-of-life data consistently shows high rates of sexual dysfunction. A 2015 study in Chest found that over 70 percent of women with PAH reported significant sexual impairment, meaning the overlap between these two drug populations is clinically real, not theoretical.

The Mechanism: Why These Two Drugs Clash

Understanding the mechanism makes the risk concrete rather than abstract.

How bremelanotide affects blood pressure

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds MC1R, MC3R, MC4R, and MC5R in the central nervous system, activating dopaminergic and noradrenergic pathways involved in sexual desire. But it also has peripheral vascular effects. Subcutaneous injection of 1.75 mg bremelanotide produces a transient increase in mean arterial pressure of approximately 1.7 mmHg within the first 12 hours, followed by a compensatory drop. In women with pre-existing cardiovascular disease or those on vasodilatory drugs, that compensatory drop can become clinically significant hypotension.

The drug is eliminated primarily via peptide hydrolysis and hepatic metabolism. It is not primarily a CYP3A4 substrate, which means the interaction with sildenafil is not pharmacokinetic but pharmacodynamic, a distinction that matters because no dose adjustment can fully mitigate a pharmacodynamic clash.

How sildenafil affects blood pressure

Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cyclic GMP in vascular smooth muscle. The result is systemic vasodilation, a drop in systemic vascular resistance, and lower blood pressure. At the 100 mg sexual-function dose, sildenafil produces a mean maximum decrease in systolic blood pressure of approximately 8.4 mmHg and diastolic of 5.5 mmHg. At the Revatio dose (20 mg three times daily), the effect is present but attenuated.

The combined effect: additive vasodilation

When you layer a melanocortin agonist with peripheral vascular rebound onto a PDE5 inhibitor causing direct vasodilation, the result is additive blood pressure lowering. Neither drug alone is high-risk for most women with normal baseline blood pressure. Together, the risk of symptomatic hypotension, lightheadedness, syncope, and reflex tachycardia rises meaningfully.

There is no published human pharmacokinetic-pharmacodynamic study specifically in women combining bremelanotide 1.75 mg with sildenafil at any dose. The contraindication rests on mechanistic reasoning and the FDA review package, not a dedicated drug-drug interaction trial in female subjects. This is a genuine evidence gap. The absence of women-specific interaction data is itself clinically important information, not a reason to assume the combination is safe.

What the FDA Label Actually Says

The bremelanotide full prescribing information (2019) states under Drug Interactions (Section 7):

"Vyleesi can cause transient blood pressure changes. Avoid use of Vyleesi in patients who are taking antihypertensive drug products or drugs that can cause hypotension, including vasodilators."

Sildenafil, as a potent vasodilator, falls squarely into the prohibited category. The label does not use the word "contraindicated" in the traditional pregnancy-category sense for this pairing, but the "avoid use" language at the drug-drug interaction level is the functional equivalent for clinical practice. Your pharmacist's drug-interaction checker will flag this as a major interaction.

The sildenafil label for Revatio similarly warns against co-administration with drugs known to produce additive hypotension.

Pharmacokinetic Details: Is There a CYP Component?

Bremelanotide does inhibit several cytochrome P450 enzymes in vitro. The FDA review documents that bremelanotide is a moderate inhibitor of CYP2C9 and a weak inhibitor of CYP3A4. Sildenafil is metabolized primarily by CYP3A4 and secondarily by CYP2C9. In theory, bremelanotide could slightly increase sildenafil plasma concentrations by slowing its hepatic clearance.

In practice, this pharmacokinetic effect is likely small at the 1.75 mg bremelanotide dose used clinically. The pharmacodynamic interaction (additive hypotension) is the dominant concern. Clinicians should not be reassured by the modest CYP overlap into thinking a small sildenafil dose is safe alongside Vyleesi.

Half-life considerations and timing

Bremelanotide is injected subcutaneously 45 minutes before anticipated sexual activity, and its terminal half-life is approximately 2.7 hours. Mean plasma concentrations fall below the limit of quantification within 12 hours in most subjects. Sildenafil taken for sexual function has a half-life of approximately 4 hours, but active metabolites persist longer. Women using sildenafil for PAH (three-times-daily dosing) have essentially continuous sildenafil exposure. There is no safe same-day dosing window when sildenafil is dosed continuously.

Sex-Specific Physiology: Why Women's PK Differs

Bremelanotide in women

The two key trials for bremelanotide, RECONNECT Study A and Study B, enrolled only premenopausal women with HSDD, so the pharmacokinetic data is actually female-derived. That is a strength. In those trials, women showed a statistically significant improvement in satisfying sexual events (SSEs) compared with placebo, with a median increase of 0.5 SSEs per month. Effect sizes were modest by any measure, which is worth knowing when you are weighing benefits against interaction risks.

Does the menstrual cycle change the interaction risk?

No published data directly addresses whether menstrual cycle phase alters bremelanotide's hemodynamic effect in women. Estrogen generally promotes endothelial nitric oxide synthesis, which means vasodilatory sensitivity may be higher in the follicular phase when estrogen peaks. This is extrapolated physiology, not studied data in the Vyleesi-sildenafil combination. Women with conditions that alter estrogen milieu, such as PCOS with anovulation or perimenopause, may have different baseline vasomotor tone, and no cycle-phase adjustment has been established.

Perimenopause and postmenopause

Vyleesi is approved only for premenopausal women. If you are in perimenopause or postmenopause and experiencing low desire, bremelanotide is not approved for your life stage. The RECONNECT trials excluded women with menopause, so there is no efficacy or safety data in this group. Postmenopausal women with low desire and who are already on sildenafil for PAH should discuss flibanserin (also approved only for premenopausal women, creating the same limitation), hormone therapy, or referral to a sexual medicine specialist.

Pregnancy, Lactation, and Contraception

Pregnancy: do not use

Bremelanotide is contraindicated in pregnancy. Animal studies showed embryo-fetal toxicity and decreased fetal body weight at doses below the human therapeutic exposure. There are no adequate human data on use during pregnancy.

The FDA assigns bremelanotide a risk-avoidance designation under the current labeling framework: the drug should be discontinued at least 4 weeks before attempting to conceive. If you use Vyleesi and your contraception fails, contact your OB-GYN and the Palatin Technologies pharmacovigilance line to report the exposure.

Sildenafil in pregnancy

Sildenafil has been studied in pregnancy for fetal growth restriction. A Dutch trial (STRIDER Netherlands) was halted early after increased neonatal death in the sildenafil arm. Sildenafil is not approved for use in pregnancy in any jurisdiction and should be discontinued before conception unless you have PAH and your cardiologist makes a risk-benefit judgment with you. PAH itself carries high maternal mortality in pregnancy, and this requires specialist co-management.

Lactation

No lactation data exist for bremelanotide in humans. Animal data suggest some transfer into milk. Given the absence of safety data and the fact that Vyleesi is a non-essential quality-of-life drug, breastfeeding women should not use it. Sildenafil transfer into breast milk is low, and the Revatio label does not prohibit breastfeeding with risk-benefit discussion, but combining either drug with breastfeeding warrants specialist input.

Contraception requirement

Because of the embryo-fetal toxicity signal, use reliable contraception while taking bremelanotide and for 4 weeks after your last dose. Combined hormonal contraceptives do not appear to substantially alter bremelanotide pharmacokinetics based on available review data, but this has not been studied as a formal interaction trial.

Who Vyleesi Is Right For, and Who It Is Not

This framework is designed to help you and your prescriber decide together.

Vyleesi may be appropriate if you:

• Are premenopausal (pre-surgically and hormonally)
• Have a confirmed diagnosis of acquired, generalized HSDD (present in multiple situations, not relationship-specific, and causing personal distress)
• Have tried addressing contributing factors (sleep deprivation, relationship distress, antidepressant-related low desire, thyroid dysfunction, PCOS-related androgen changes) without sufficient improvement
• Are not taking sildenafil, any nitrate, or antihypertensive drug that the label lists as a concern
• Have a baseline blood pressure above 90/55 mmHg (women with pre-existing hypotension are not good candidates)
• Are not pregnant and using reliable contraception

Vyleesi is not appropriate if you:

• Take sildenafil for any reason (PAH or otherwise)
• Take other PDE5 inhibitors (tadalafil, vardenafil, avanafil)
• Take nitrates (isosorbide mononitrate, isosorbide dinitrate, nitroglycerin)
• Are pregnant or planning pregnancy within 4 weeks
• Are breastfeeding
• Are in perimenopause or postmenopause (outside the approved population)
• Have uncontrolled hypertension or a recent cardiovascular event (the transient BP shift adds risk)
• Have a history of hypersensitivity to bremelanotide or the formulation components

Monitoring and What to Tell Your Prescriber

If your clinician is considering Vyleesi and you are on any cardiovascular drug, including sildenafil:

1. Provide a complete medication list, including supplements and any drugs prescribed by a different specialist (your cardiologist may have prescribed Revatio without knowing your gynecologist is considering Vyleesi).
2. Ask for a blood pressure check at baseline. The FDA label recommends measuring BP before each use. Women with a resting BP below 90/55 mmHg should not use bremelanotide.
3. Report every episode of dizziness, lightheadedness, or near-fainting after Vyleesi injection. These are the clinical signals of the hypotensive interaction in action.
4. Do not substitute timing tricks for a medication change. Because sildenafil used for PAH is dosed continuously, there is no safe window to use Vyleesi on a "sildenafil-free" day.

Alternatives for Women Who Cannot Use Vyleesi Because of Sildenafil

If you have HSDD and sildenafil is a firm part of your treatment plan, these options may be worth discussing:

Flibanserin (Addyi)

Flibanserin is the other FDA-approved HSDD drug for premenopausal women. It works via serotonin and dopamine receptor modulation. Its own interaction profile is different: the major concern is alcohol (additive CNS depression and hypotension) and CYP3A4 inhibitors. Flibanserin does not carry the same vasodilatory pharmacodynamic interaction as bremelanotide, making it a more plausible option for women on continuous sildenafil, though your prescriber should still review all interactions on a case-by-case basis.

Testosterone off-label

Low-dose testosterone therapy is used off-label for HSDD in premenopausal and postmenopausal women outside the US and within clinical practice guidelines of some organizations. The International Society for the Study of Women's Sexual Health (ISSWSH) published a position statement supporting testosterone for HSDD with certain evidence thresholds. Testosterone does not carry the blood pressure interaction seen with bremelanotide, making it mechanistically compatible with sildenafil use, though formal co-administration data are not available.

Psychotherapy and sex therapy

Cognitive behavioral therapy and mindfulness-based sex therapy have evidence of moderate efficacy for HSDD and no drug interactions. For women in whom pharmacological options are limited by comorbid drug therapy, this may be the first-line approach.

A Note on Off-Label Sildenafil for Female Sexual Dysfunction

Some clinicians prescribe sildenafil off-label to women for arousal disorder or orgasmic dysfunction. The evidence is limited. A Cochrane review found inconsistent benefit of PDE5 inhibitors for female sexual dysfunction and the overall quality of trial data is low. If your sildenafil was prescribed off-label for sexual function rather than PAH, it is worth re-evaluating with your prescriber whether it is providing meaningful benefit, because the interaction with Vyleesi may mean you need to choose one drug over the other.

Women have been under-represented in PDE5 inhibitor trials. Most sildenafil dosing and interaction data comes from male subjects. The hemodynamic effects in women may differ because of sex differences in body composition, hormonal modulation of vascular tone, and differences in CYP3A4 activity across the menstrual cycle. Extrapolating male interaction data to women is standard practice here but is acknowledged extrapolation, not direct evidence.

Practical Counseling Points Before Your First Vyleesi Dose

• Inject bremelanotide 1.75 mg subcutaneously into the abdomen or thigh, not the forearm, at least 45 minutes before anticipated sexual activity.
• Do not use more than one dose within 24 hours and no more than approximately 8 doses per month based on the clinical trial design.
• Nausea is the most common side effect, reported in approximately 40 percent of women in the RECONNECT trials, typically peaking within 1 hour and resolving within 12 hours. An antiemetic taken 30 minutes before injection reduces this substantially.
• Transient flushing and hyperpigmentation with prolonged use (focal, gingival, or facial) have been reported and may be more noticeable in women with darker skin tones.
• Blood pressure should be checked before each dose if you have any cardiovascular risk factor.

If you are on sildenafil and your HSDD is significantly affecting your quality of life, bring both prescribers into the same conversation. A cardiologist managing your PAH and a gynecologist or sexual medicine specialist managing your HSDD may not know about each other's prescriptions. The burden of reconciling these prescriptions should not fall on you alone, but knowing about this specific interaction means you can raise it directly.